Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Clearside Biomedical Inc CLSD

Healthcare
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or... see more

Recent & Breaking News (NDAQ:CLSD)

Clearside Biomedical Announces Leadership Team Update

GlobeNewswire February 6, 2023

Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD

GlobeNewswire February 2, 2023

Clearside Biomedical to Participate in Multiple Upcoming Investor and Ophthalmology Conferences in November and December 2022

GlobeNewswire November 22, 2022

Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2022 Healthcare Conference

GlobeNewswire November 10, 2022

Clearside Biomedical Announces Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2022

Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients

GlobeNewswire November 9, 2022

Clearside Biomedical to Report OASIS Phase 1/2a Clinical Trial Results and Host Conference Call on Wednesday, November 9, 2022 in Conjunction with Third Quarter 2022 Financial Results

GlobeNewswire November 8, 2022

Clearside Biomedical to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Wednesday, November 9, 2022

GlobeNewswire November 2, 2022

Positive Data Presentations at AAO Annual Meeting Demonstrate Utility and Versatility of Clearside Biomedical's Proprietary Suprachoroidal Space Platform

GlobeNewswire October 4, 2022

Clearside Biomedical to Present Corporate Overview and Upcoming Catalysts at Eyecelerator at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting

GlobeNewswire September 27, 2022

Clearside Biomedical to Present at the Ophthalmology Futures Retina Forum 2022

GlobeNewswire August 25, 2022

Clearside Biomedical Announces Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 9, 2022

Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million

GlobeNewswire August 8, 2022

Clearside Biomedical to Participate in Three Upcoming Investor Conferences in August 2022

GlobeNewswire August 3, 2022

Clearside Biomedical to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Tuesday, August 9, 2022

GlobeNewswire July 27, 2022

Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients

GlobeNewswire July 26, 2022

Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings

GlobeNewswire July 7, 2022

Clearside Biomedical Expands Leadership Team with Appointment of Susan Coultas, Ph.D., as Chief Clinical Officer

GlobeNewswire June 14, 2022

Clearside Biomedical to Participate in the JMP Securities Life Sciences Conference

GlobeNewswire June 8, 2022

Clearside Biomedical Announces First Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire May 11, 2022